Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population

References

• American Cancer Society. Pancreatic Cancer. 2013; http://www.cancer.org/acs/groups/cid/documents/webcontent/003131-pdf.pdf. Accessed August 12, 2013
   Google Scholar
• Siegel R, Jemal A, Naishadham D. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
   PubMed Web of Science ®Google Scholar
• el-Kamar FG, Grossbard ML, Kozuch PS. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003;8:18-34
   PubMedGoogle Scholar
• Li J, Wientjes MG, Au JL. Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J 2010;12:223-32
   Google Scholar
• Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267
   PubMed Web of Science ®Google Scholar
• Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
   PubMed Web of Science ®Google Scholar
• Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160-4
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16
   PubMed Web of Science ®Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7
   PubMed Web of Science ®Google Scholar
• De Jesus-Acosta A, Oliver GR, Blackford A, et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012; 69:415-24.
   PubMedGoogle Scholar
• Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012;10:703-13
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Guidelines. Pancreatic Adenocarcinoma Version 1.2013. 2013; http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed July 2013
   Google Scholar
• Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605-10
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-22
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Trends Progress Report. 2012; http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2007&chid=75&coid=726&. Accessed May 29, 2012
   Google Scholar
• Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004;22:3524-30
   PubMed Web of Science ®Google Scholar
• O'Neill CB, Atoria CL, O'Reilly EM, et al. Costs and trends in pancreatic cancer treatment. Cancer 2012;118:5132-9
   PubMed Web of Science ®Google Scholar
• Du W, Touchette D, Vaitkevicius VK, et al. Cost analysis of pancreatic carcinoma treatment. Cancer 2000;89:1917-24
   PubMed Web of Science ®Google Scholar
• Chang S, Long SR, Kutikova L, et al. Burden of pancreatic cancer and disease progression: economic analysis in the US. Oncology 2006;70:71-80
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 2010;28(Suppl):abstr 4010
   Google Scholar
• Arlen AG, Cartwright TH, Wilfong LS, et al. Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine. J Clin Oncol 2012;30(Suppl):abstr 16536
   Google Scholar
• Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 2012;30(Suppl 34):abstr LBA148
   Google Scholar
• Eichler AF, Lamont EB. Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol 2009;95:427-31
   PubMed Web of Science ®Google Scholar